DE60225701D1 - Ophthalmische depot-formulierungen zur periokkularen oder subkonjunktivalen verabreichung - Google Patents
Ophthalmische depot-formulierungen zur periokkularen oder subkonjunktivalen verabreichungInfo
- Publication number
- DE60225701D1 DE60225701D1 DE60225701T DE60225701T DE60225701D1 DE 60225701 D1 DE60225701 D1 DE 60225701D1 DE 60225701 T DE60225701 T DE 60225701T DE 60225701 T DE60225701 T DE 60225701T DE 60225701 D1 DE60225701 D1 DE 60225701D1
- Authority
- DE
- Germany
- Prior art keywords
- periocular
- depot formulations
- subconjunctival administration
- ophthalmic depot
- ophthalmic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0122318.9A GB0122318D0 (en) | 2001-09-14 | 2001-09-14 | Organic compounds |
GB0122318 | 2001-09-14 | ||
PCT/EP2002/010314 WO2003024420A1 (en) | 2001-09-14 | 2002-09-13 | Ophthalmic depot formulations for periocular or subconjunctival administration |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60225701D1 true DE60225701D1 (de) | 2008-04-30 |
DE60225701T2 DE60225701T2 (de) | 2009-04-30 |
Family
ID=9922147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60225701T Expired - Lifetime DE60225701T2 (de) | 2001-09-14 | 2002-09-13 | Ophthalmische depot-formulierungen zur periokkularen oder subkonjunktivalen verabreichung |
Country Status (25)
Country | Link |
---|---|
US (4) | US20040234611A1 (de) |
EP (1) | EP1429725B1 (de) |
JP (3) | JP2005504797A (de) |
KR (1) | KR20040030869A (de) |
CN (2) | CN1538835A (de) |
AT (1) | ATE389385T1 (de) |
AU (1) | AU2002342694B2 (de) |
BR (1) | BR0212475A (de) |
CA (1) | CA2455680C (de) |
CO (1) | CO5560548A2 (de) |
DE (1) | DE60225701T2 (de) |
EC (1) | ECSP044967A (de) |
ES (1) | ES2302849T3 (de) |
GB (1) | GB0122318D0 (de) |
HK (1) | HK1066733A1 (de) |
HU (1) | HU229453B1 (de) |
IL (2) | IL160027A0 (de) |
MX (1) | MXPA04002421A (de) |
NO (1) | NO333825B1 (de) |
NZ (1) | NZ531481A (de) |
PL (1) | PL203949B1 (de) |
PT (1) | PT1429725E (de) |
RU (1) | RU2316315C2 (de) |
WO (1) | WO2003024420A1 (de) |
ZA (1) | ZA200400524B (de) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US20060177416A1 (en) | 2003-10-14 | 2006-08-10 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20030119812A1 (en) * | 2001-11-08 | 2003-06-26 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
DK1539157T3 (da) | 2002-09-18 | 2013-10-07 | Univ Pennsylvania | Fremgangsmåde til hæmning af choroidal neovaskularisering |
US9216106B2 (en) | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
US20050009910A1 (en) * | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
CN1835735B (zh) * | 2003-08-20 | 2010-05-12 | 参天制药株式会社 | 微粒眼球筋膜下给药的药物释放系统 |
WO2005072701A1 (en) * | 2004-01-20 | 2005-08-11 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
AU2011213904B2 (en) * | 2004-04-30 | 2014-06-05 | Allergan, Inc. | Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
BRPI0607606B1 (pt) | 2005-02-09 | 2021-06-22 | Santen Pharmaceutical, Co., Ltd. | Formulação líquida |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
JP2006257080A (ja) * | 2005-02-18 | 2006-09-28 | Santen Pharmaceut Co Ltd | ステロイド化合物の副作用軽減または回避方法 |
US8440217B1 (en) * | 2005-06-15 | 2013-05-14 | Mawaheb M. EL-Naggar | Method and system with contact lens product for treating and preventing adverse eye conditions |
WO2013059629A1 (en) | 2011-10-21 | 2013-04-25 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
US20160045457A1 (en) | 2005-09-09 | 2016-02-18 | Ousama Rachid | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
US9877921B2 (en) | 2005-09-09 | 2018-01-30 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
WO2007035938A2 (en) | 2005-09-22 | 2007-03-29 | Medivas, Llc | BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE |
JP5178520B2 (ja) | 2005-09-22 | 2013-04-10 | メディバス エルエルシー | 固体ポリマー送達組成物およびその使用法 |
EP2001438A2 (de) | 2006-02-09 | 2008-12-17 | Macusight, Inc. | Stabile formulierungen sowie verfahren zu ihrer herstellung und verwendung |
JP5506378B2 (ja) | 2006-03-23 | 2014-05-28 | 参天製薬株式会社 | 血管透過性に関連する疾患または病気のための製剤および方法 |
US20070292476A1 (en) * | 2006-05-02 | 2007-12-20 | Medivas, Llc | Delivery of ophthalmologic agents to the exterior or interior of the eye |
US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US8492334B2 (en) * | 2007-06-21 | 2013-07-23 | Yale University | Sustained intraocular delivery of drugs from biodegradable polymeric microparticles |
US20110206773A1 (en) * | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
KR20180117211A (ko) | 2010-01-22 | 2018-10-26 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
CA2791278C (en) | 2010-02-25 | 2015-11-24 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
US20120322884A1 (en) | 2010-03-01 | 2012-12-20 | University Of Manitoba | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
RU2456979C1 (ru) * | 2011-04-11 | 2012-07-27 | Общество с ограниченной ответственностью "ЭкоБиоФармДубна" | Индометацин на основе фосфолипидных наночастиц для применения в офтальмологии |
US9873765B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
CA2839526A1 (en) | 2011-06-23 | 2012-12-27 | Dsm Ip Assets B.V. | Micro- or nanoparticles comprising a biodegradable polyesteramide copolymer for use in the delivery of bioactive agents |
AU2013209452B2 (en) | 2012-01-19 | 2015-11-05 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
KR102183727B1 (ko) * | 2012-01-23 | 2020-11-27 | 알러간, 인코포레이티드 | 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자 |
US10159743B2 (en) | 2012-03-16 | 2018-12-25 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
EP2825206A1 (de) | 2012-03-16 | 2015-01-21 | The Johns Hopkins University | Formulierungen mit kontrollierter freisetzung zur verabreichung von hif-1-hemmern |
EP4008355A1 (de) | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmazeutische nanopartikel mit verbessertem mukosalem transport |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP3808339A1 (de) | 2012-05-03 | 2021-04-21 | Kala Pharmaceuticals, Inc. | Pharmazeutische nanopartikel mit verbessertem mukosalem transport |
EP2849728A1 (de) | 2012-05-04 | 2015-03-25 | The Johns Hopkins University | Arzneimittelträger auf lipidbasis zur schnellen penetration durch schleimauskleidungen |
EP2861224A4 (de) * | 2012-06-15 | 2015-11-18 | Univ Nova Southeastern | Epinephrinnanopartikel, verfahren zur herstellung davon und verfahren zur verwendung davon zur behandlung von auf epinephrin ansprechenden leiden |
WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
HUE055773T2 (hu) | 2013-03-22 | 2021-12-28 | Univ Nova Southeastern | Epinefrin finom részecskék és módszerek azok alkalmazására az epinefrinre reagáló állapotok kezelésében |
KR20150139899A (ko) | 2013-04-01 | 2015-12-14 | 알러간, 인코포레이티드 | 지속적인 안구내 방출을 위한 마이크로스피어 약물 전달 시스템 |
RU2650614C2 (ru) | 2013-10-31 | 2018-04-16 | Аллерган, Инк. | Внутриглазные имплантаты, содержащие простамид, и способы их применения |
WO2015127389A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic enema formulations and methods of use |
EP3169308B1 (de) | 2014-07-18 | 2021-01-27 | Allergan, Inc. | Suspensionen von cyclosporin a zur subkonjunktivalen und periokularen injektion |
RU2616258C2 (ru) * | 2014-11-10 | 2017-04-13 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Способ получения полимерных наночастиц низкосиалированного эритропоэтина с высокой степенью сорбции для лечения неврологических заболеваний |
AU2015362621B2 (en) | 2014-12-15 | 2019-01-17 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of ocular disorders |
AU2015366355B2 (en) | 2014-12-18 | 2020-05-28 | Dsm Ip Assets B.V. | Drug delivery system for delivery of acid sensitive drugs |
AU2016211696B2 (en) | 2015-01-27 | 2018-05-10 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
EP3340982B1 (de) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Verbindungen zur behandlung von immun- und entzündungserkrankungen |
CN114469872A (zh) | 2015-11-12 | 2022-05-13 | 灰色视觉公司 | 用于治疗的聚集性微粒 |
EP3455218A4 (de) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Mit c3-kohlenstoff verknüpfte glutarimiddegronimere zum zielproteinabbau |
EP3454856A4 (de) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | Heterocyclische degronimere für zielproteinabbau |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
US11395853B2 (en) * | 2016-06-23 | 2022-07-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions |
RU2018145364A (ru) | 2016-06-27 | 2020-07-28 | Ачиллион Фармасьютикалс, Инк. | Хиназолиновые и индольные соединения для лечения медицинских нарушений |
WO2018005860A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
CN107397745A (zh) * | 2016-08-24 | 2017-11-28 | 上海毕傲图生物科技有限公司 | 唑类化合物眼用制剂 |
BR112019019452A2 (pt) | 2017-03-23 | 2020-04-14 | Graybug Vision Inc | composto, e, uso de um composto |
US11160870B2 (en) | 2017-05-10 | 2021-11-02 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
US20210121534A1 (en) * | 2018-06-19 | 2021-04-29 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
EP3866773A4 (de) | 2018-10-16 | 2022-10-26 | Georgia State University Research Foundation, Inc. | Kohlenmonoxid-prodrugs zur behandlung von erkrankungen |
CN114786480B (zh) * | 2019-10-30 | 2024-03-29 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
MX2022009677A (es) | 2020-02-06 | 2022-09-09 | Perfuse Therapeutics Inc | Composiciones para el tratamiento de enfermedades oculares. |
WO2022232588A1 (en) | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3960150A (en) * | 1971-09-09 | 1976-06-01 | Alza Corporation | Bioerodible ocular device |
BE788575A (fr) * | 1971-09-09 | 1973-01-02 | Alza Corp | Dispositif oculaire pour l'administration d'un |
US4177256A (en) * | 1973-04-25 | 1979-12-04 | Alza Corporation | Osmotic bursting drug delivery device |
GB1425550A (en) * | 1973-04-25 | 1976-02-18 | Alza Corp | Device for releasing active agent and process for producing the same |
US3914402A (en) * | 1973-06-14 | 1975-10-21 | Alza Corp | Ophthalmic dosage form, for releasing medication over time |
CH656884A5 (de) * | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
DE3722837A1 (de) * | 1987-07-10 | 1989-01-19 | Ruetgerswerke Ag | Ophthalmisches depotpraeparat |
US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4865846A (en) * | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
JPH05507683A (ja) * | 1990-04-27 | 1993-11-04 | アラーガン、インコーポレイテッド | ポリマードラッグデリバリーシステム |
WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5801146A (en) * | 1996-05-03 | 1998-09-01 | Abbott Laboratories | Compound and method for inhibiting angiogenesis |
DE69705746T2 (de) * | 1996-12-20 | 2001-10-31 | Alza Corp | Injizierbare depotgelzubereitung und herstellungsverfahren |
ATE371453T1 (de) * | 1998-08-13 | 2007-09-15 | Novartis Pharma Gmbh | Verfahren zur behandlung von okularen neovaskularen erkrankungen |
CN1172673C (zh) * | 1998-11-23 | 2004-10-27 | 诺瓦提斯公司 | 星形孢菌素衍生物在制备治疗眼睛新血管生成性疾病的药物中的应用 |
CZ20023174A3 (cs) * | 2000-03-24 | 2003-01-15 | Novartis Ag | Farmaceutické prostředky obsahující antiangiogenní léčivo a fotosenzitivní činidlo |
CA2423431A1 (en) * | 2000-10-06 | 2002-04-11 | Durect Corporation | Devices and methods for management of inflammation |
US6673802B2 (en) * | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
-
2001
- 2001-09-14 GB GBGB0122318.9A patent/GB0122318D0/en not_active Ceased
-
2002
- 2002-09-13 WO PCT/EP2002/010314 patent/WO2003024420A1/en active IP Right Grant
- 2002-09-13 AT AT02779354T patent/ATE389385T1/de active
- 2002-09-13 CA CA2455680A patent/CA2455680C/en not_active Expired - Fee Related
- 2002-09-13 CN CNA028155742A patent/CN1538835A/zh active Pending
- 2002-09-13 EP EP02779354A patent/EP1429725B1/de not_active Expired - Lifetime
- 2002-09-13 RU RU2004111596/15A patent/RU2316315C2/ru not_active IP Right Cessation
- 2002-09-13 BR BR0212475-0A patent/BR0212475A/pt not_active IP Right Cessation
- 2002-09-13 PT PT02779354T patent/PT1429725E/pt unknown
- 2002-09-13 IL IL16002702A patent/IL160027A0/xx unknown
- 2002-09-13 HU HU0401568A patent/HU229453B1/hu not_active IP Right Cessation
- 2002-09-13 CN CN2010105534172A patent/CN102008428A/zh active Pending
- 2002-09-13 KR KR10-2004-7001255A patent/KR20040030869A/ko active Search and Examination
- 2002-09-13 ES ES02779354T patent/ES2302849T3/es not_active Expired - Lifetime
- 2002-09-13 NZ NZ531481A patent/NZ531481A/en not_active IP Right Cessation
- 2002-09-13 US US10/489,752 patent/US20040234611A1/en not_active Abandoned
- 2002-09-13 MX MXPA04002421A patent/MXPA04002421A/es active IP Right Grant
- 2002-09-13 DE DE60225701T patent/DE60225701T2/de not_active Expired - Lifetime
- 2002-09-13 AU AU2002342694A patent/AU2002342694B2/en not_active Ceased
- 2002-09-13 PL PL368128A patent/PL203949B1/pl not_active IP Right Cessation
- 2002-09-13 JP JP2003528517A patent/JP2005504797A/ja not_active Withdrawn
-
2004
- 2004-01-22 IL IL160027A patent/IL160027A/en not_active IP Right Cessation
- 2004-01-23 ZA ZA200400524A patent/ZA200400524B/en unknown
- 2004-02-02 EC EC2004004967A patent/ECSP044967A/es unknown
- 2004-02-18 CO CO04013821A patent/CO5560548A2/es not_active Application Discontinuation
- 2004-03-02 NO NO20040917A patent/NO333825B1/no not_active IP Right Cessation
- 2004-12-10 HK HK04109814A patent/HK1066733A1/xx unknown
-
2008
- 2008-08-20 US US12/194,617 patent/US20080305172A1/en not_active Abandoned
-
2010
- 2010-10-01 JP JP2010224231A patent/JP2011026338A/ja not_active Withdrawn
-
2012
- 2012-06-14 US US13/523,537 patent/US20120269894A1/en not_active Abandoned
-
2013
- 2013-01-07 US US13/735,076 patent/US20130122064A1/en not_active Abandoned
- 2013-05-09 JP JP2013099024A patent/JP2013147516A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60225701D1 (de) | Ophthalmische depot-formulierungen zur periokkularen oder subkonjunktivalen verabreichung | |
PT1401501E (pt) | Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo | |
WO2004064769A3 (en) | Methods for making and using topical delivery agents | |
WO2002100437A3 (en) | Ophthalmic compositions comprising hyaluronic acid | |
MX2009009463A (es) | Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo. | |
UA85574C2 (uk) | Ендопаразитоцидний засіб для місцевого застосування | |
CY1110906T1 (el) | Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης | |
BR0308486A (pt) | Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga | |
PT1121127E (pt) | Composicoes farmaceuticas orais contendo buprenorfina | |
SG149872A1 (en) | Antagonists of the bradykinin b1 receptor | |
DE60102590D1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
ATE454136T1 (de) | Therapeutische zusammensetzungen zur pulmonalen verabreichung | |
PL1713438T3 (pl) | Mydło lecznicze | |
IL166596A0 (en) | Salt of morphine-6-glucoronide | |
MXPA05014184A (es) | Utilizacion de acido hialuronico para la preparacion de composiciones para el tratamiento de aftas en la cavidad oral. | |
BRPI0417265A (pt) | composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna | |
WO2002004012A8 (en) | Anhydrous pharmaceutical composition of vancomycin for topical use | |
TNSN06113A1 (en) | Antagonists of the bradykinin b1 receptor | |
SE0203817D0 (sv) | New composition | |
MXPA01009032A (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12. | |
UA92344C2 (ru) | Топичная композиция, содержащая рыбный желатин | |
DE60233819D1 (de) | Doppelester | |
MXPA04006675A (es) | Composicion farmaceutica que comprende glitazona y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes. | |
WO2002055068A3 (fr) | Cystine par voie orale pour traiter l'oeil sec | |
TR200301916T4 (tr) | Rotigotinin yüksek plazma seviyelerini kapsayan parkinson hastalığına yönelik transdermal terapötik sistem. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |